Precision of Vancomycin and Daptomycin MICs for Methicillin-Resistant Staphylococcus aureus and Effect of Subculture and Storage

被引:24
作者
Charlton, Carmen L. [1 ,2 ]
Hindler, Janet A. [1 ]
Turnidge, John [3 ,4 ]
Humphries, Romney M. [1 ]
机构
[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA
[2] Alberta Hlth Serv, Edmonton, AB, Canada
[3] Womens & Childrens Hosp, SA Pathol, Adelaide, SA, Australia
[4] Univ Adelaide, Dept Paediat Pathol & Mol & Biomed Sci, Adelaide, SA, Australia
关键词
MINIMUM INHIBITORY CONCENTRATION; BACTERICIDAL ACTIVITY; SUSCEPTIBILITY; BACTEREMIA; INTERMEDIATE; INFECTIONS; EFFICACY; ETEST; PRODUCTS; THERAPY;
D O I
10.1128/JCM.01571-14
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The reproducibility of vancomycin and daptomycin MICs, measured by broth microdilution (BMD) and Etest, was prospectively assessed for 10 methicillin-resistant Staphylococcus aureus (MRSA) isolates from the blood samples from patients on vancomycin therapy. The isolates were tested at the time of isolation from blood and following 5, 10, and 20 subcultures and at 1, 3, 6, and 12 months of storage at -70 degrees C. The MICs were determined by Etest and BMD using two different manufacturers (BBL and Difco) of cation-adjusted Mueller-Hinton broth (CA-MHB), and using three different drug powders: vancomycin from Sigma, vancomycin from Novation, and daptomycin from Cubist. The antimicrobial concentrations tested were 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, and 4.0 mu g/ml. Two isolates were vancomycin intermediate and daptomycin nonsusceptible, and two isolates had reduced susceptibility to vancomycin (BMD MIC, 1.5 or 2.0 mu g/ml). The vancomycin MICs were significantly higher in the BBL CA-MHB than those in the Difco CA-MHB, and with Sigma versus Novation vancomycin powder. The daptomycin MICs were also significantly higher in the BBL CA-MHB. The Etest MICs were significantly higher than those obtained by BMD for vancomycin but not for daptomycin. The average precision of the vancomycin BMD MICs when analyzing 20 results was +/- 1.10-fold log(2) dilutions, and it was +/- 1.67-fold for daptomycin (10 results). The average precision for Etest was +/- 1.11-fold for vancomycin and +/- 1.16-fold for daptomycin. No significant change in MICs was noted following 5, 10, or 20 subcultures or at up to 6 months of frozen storage. However, the vancomycin MICs alone were significantly lower (0.74-fold) following 12 months of frozen storage. From these data, despite variations in CA-MHB and antimicrobial powder, the MIC result precision was <0.5 log(2) dilutions in a single laboratory, suggesting that testing interdilution MICs (e.g., MICs between serial 2-fold dilutions) is a possibility. A more accurate method for measuring vancomycin MIC results is thus possible, but further standardization of BMD testing would be required to achieve this goal.
引用
收藏
页码:3898 / 3905
页数:8
相关论文
共 35 条
[11]   High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections -: Efficacy and toxicity [J].
Hidayat, Levita K. ;
Hsu, Donald I. ;
Quist, Ryan ;
Shriner, Kimberly A. ;
Wong-Beringer, Annie .
ARCHIVES OF INTERNAL MEDICINE, 2006, 166 (19) :2138-2144
[12]   Vancomycin AUC/MIC Ratio and 30-Day Mortality in Patients with Staphylococcus aureus Bacteremia [J].
Holmes, Natasha E. ;
Turnidge, John D. ;
Munckhof, Wendy J. ;
Robinson, J. Owen ;
Korman, Tony M. ;
O'Sullivan, Matthew V. N. ;
Anderson, Tara L. ;
Roberts, Sally A. ;
Warren, Sanchia J. C. ;
Gao, Wei ;
Howden, Benjamin P. ;
Johnson, Paul D. R. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (04) :1654-1663
[13]   Reduced Vancomycin Susceptibility in Staphylococcus aureus, Including Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Strains: Resistance Mechanisms, Laboratory Detection, and Clinical Implications [J].
Howden, Benjamin P. ;
Davies, John K. ;
Johnson, Paul D. R. ;
Stinear, Timothy P. ;
Grayson, M. Lindsay .
CLINICAL MICROBIOLOGY REVIEWS, 2010, 23 (01) :99-+
[14]   Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections [J].
Hsu, Donald I. ;
Hidayat, Levita K. ;
Quist, Ryan ;
Hindler, Janet ;
Karlsson, Asa ;
Yusof, Anne ;
Wong-Beringer, Annie .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2008, 32 (05) :378-385
[15]   A Current Perspective on Daptomycin for the Clinical Microbiologist [J].
Humphries, Romney M. ;
Pollett, Simon ;
Sakoulas, George .
CLINICAL MICROBIOLOGY REVIEWS, 2013, 26 (04) :759-780
[16]   Should Laboratories Test Methicillin-Resistant Staphylococcus aureus for Elevated Vancomycin Minimum Inhibitory Concentrations by Etest as a Driver of Treatment Changes? [J].
Humphries, Romney M. ;
Hindler, Janet A. .
CLINICAL INFECTIOUS DISEASES, 2012, 55 (04) :612-613
[17]  
ISO, 2006, 207762 ISO
[18]   Antimicrobial Susceptibility Testing: A Review of General Principles and Contemporary Practices [J].
Jorgensen, James H. ;
Ferraro, Mary Jane .
CLINICAL INFECTIOUS DISEASES, 2009, 49 (11) :1749-1755
[19]   Evaluation of the Etest GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptides [J].
Leonard, Steven N. ;
Rossi, Kerri L. ;
Newton, Karly L. ;
Rybak, Michael J. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 63 (03) :489-492
[20]   Case-control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 μg/mL and risk factors, costs, and outcomes in inpatients undergoing hemodialysis [J].
Maclayton, Darego O. ;
Suda, Katie J. ;
Coval, Krista A. ;
York, Cynthia B. ;
Garey, Kevin W. .
CLINICAL THERAPEUTICS, 2006, 28 (08) :1208-1216